Compare Morgan Stanley (MS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Spyre Therapeutics Inc. Common Stock — how do they compare? Morgan Stanley trades at $182.09 (market cap $285.07B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Morgan Stanley is far larger — about 38.8× Spyre Therapeutics Inc. Common Stock's market cap, and Morgan Stanley pays a 2.53% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 90 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MS | SYRE | |
|---|---|---|
Market Cap | $285.07B | $7.35B |
Volume | 8,664,533 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $228.42 | $108.92 |
52-Week Low | $154.37 | $22.18 |
Typical Hold Time | 90 Days | 0 Days |
Enterprise Value | $286.44B | $6.35B |
Dividend Yield | 2.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $186.66, down 1.77% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $50.2B in 2022 to $66.0B in 2025, and a net income margin of 27.59%. Analyst consensus is bullish with a $225.50 price target, supported by growth in wealth management and AI financing.
The outlook remains positive given earnings momentum and strategic initiatives, but risks include volatile cash flows, high debt levels, and market sensitivity. Upside potential exists if the company capitalizes on capital markets recovery and AI demand, though investors should monitor leverage and macroeconomic headwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
